Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

M. S. Sulkowski, J. J. Feld, E. Lawitz, F. Felizarta, A. M. Corregidor, O. Khalid, R. Ghalib, W. B. Smith, V. Van Eygen, D. Luo, L. Vijgen, M. Gamil, T. N. Kakuda, S. Ouwerkerk-Mahadevan, P. Van Remoortere, M. Beumont

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection'. Together they form a unique fingerprint.

Medicine & Life Sciences